Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
IPO Year: 2013
Exchange: NASDAQ
Website: tandemdiabetes.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/4/2024 | $46.00 | Neutral | Goldman |
10/2/2024 | $65.00 | Outperform | RBC Capital Mkts |
8/22/2024 | $45.00 | Equal-Weight | Morgan Stanley |
8/8/2024 | $57.00 | Buy | Canaccord Genuity |
5/30/2024 | $60.00 | Buy | Redburn Atlantic |
5/22/2024 | $40.00 → $57.00 | Neutral → Buy | Citigroup |
4/29/2024 | $21.00 → $45.00 | Equal Weight → Overweight | Wells Fargo |
4/25/2024 | $34.00 → $45.00 | Market Perform → Outperform | Leerink Partners |
3/26/2024 | $24.00 → $37.00 | Hold → Buy | Stifel |
8/4/2023 | $45.00 → $33.00 | Buy → Neutral | Citigroup |
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that management will host meetings and present a company update at the following investor conferences: UBS Global Healthcare Conference on Thursday, November 14, 2024 at 11:45am Eastern Time (8:45am Pacific Time), Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 at 11:30am Eastern Time (8:30am Pacific Time), Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 4:30pm GMT (11:30am ET, 8:30am PT), and Wolfe Research Healthcare Conference on Wednesday, November 20, 2024 at 8:40am Eastern Time (5:40am Pacific Time). In addition, the
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2024 results after the financial markets close on Wednesday, November 6, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2024 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register.vevent.com/register/BI21747dfdc3fd4a
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the European Union (EU). "High satisfaction and quality of life benefits were recently shown in a clinical study using Lyumjev with Control-IQ technology,"1 said Jordan Pinsker, MD, Chief Medical Officer at Tandem Diabetes Care. "Ultra-rapid acting insulin is a popular choice for people living with diabetes due to its fast response time. We are proud to be able t
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that management will host meetings and present a company update at the following investor conferences: 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 2:15 pm Eastern Time (11:15 am Pacific Time), Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024 at 12:20 pm Eastern Time (9:20 am Pacific Time), and Baird 2024 Global Healthcare Conference on Wednesday, September 11, 2024 at 9:40 am Eastern Time (6:40 am Pacific Time). In addition, the Company will host meetings at the Lake Street Capital Markets 8th Annua
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) today announced the planned release of version 2.8.2 of its Apple iOS t:connect mobile app in the United States on August 20, 2024 to correct an issue described in a March 2024 recall that can cause rapid depletion of a user's t:slim X2 insulin pump battery. This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to see following the release of version 2.7.1 of the app in March. Tandem encourages all impacted t:slim X2 iOS users to update their mobile app as soon as the new version is available in the Apple App Store. Under-delivery of insulin because of a pump shutdown can result in hyp
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) today provided an update on the March 2024 recall of its Apple iOS t:connect mobile app in the United States relating to an issue that can cause rapid depletion of a user's t:slim X2 insulin pump battery. This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to experience following the release of version 2.7.1 of the app in March. Notices were emailed to impacted customers on August 9, 2024 with updated information and recommendations for helping avoid pump battery depletion. Tandem plans to release a new version of the app to address the remaining issues and will notify all users by ema
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2024 and increased sales guidance for the year ending December 31, 2024. Second Quarter 2024 Highlights Worldwide GAAP sales increased 13 percent to $221.9 million compared to second quarter 2023; worldwide non-GAAP sales(1) increased 12 percent to $221.8 million compared to second quarter 2023. More than 20,000 pumps shipped in the United States, a sequential increase of 33 percent compared to first quarter 2024. Launched Tandem Mobi with Dexcom G7 continuous glucose monitoring (CGM) sensor integration in the Uni
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 1:30pm Eastern Time (10:30am Pacific Time). The presentation will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. About Tandem Diabetes Care, Inc. Tandem Diabetes Care, a global insulin delivery and diabetes technology co
– Only Automated Insulin Delivery System in Canada to Feature Both Dexcom G7 and G6 CGM Technology Now Authorized for Sale by Health Canada – Tandem Diabetes Care, Inc. (NASDAQ:TNDM) and Dexcom, Inc. (NASDAQ:DXCM) today announced the updated t:slim X2™ insulin pump software is compatible with both Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems and is authorized for sale by Health Canada. This integration allows users of the t:slim X2 insulin pump with Control-IQ technology, the #1 rated automated insulin delivery (AID) system in Canada,* to have even more choice in how they manage their diabetes. This press release features multimedia. View the full release here: htt
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024 results after the financial markets close on Thursday, August 1, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2024 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register.vevent.com/register/BIc1efe0f41c4149
For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2024 results after the financial markets close on Wednesday, November 6, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2024 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register.vevent.com/register/BI21747dfdc3fd4a
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2024 and increased sales guidance for the year ending December 31, 2024. Second Quarter 2024 Highlights Worldwide GAAP sales increased 13 percent to $221.9 million compared to second quarter 2023; worldwide non-GAAP sales(1) increased 12 percent to $221.8 million compared to second quarter 2023. More than 20,000 pumps shipped in the United States, a sequential increase of 33 percent compared to first quarter 2024. Launched Tandem Mobi with Dexcom G7 continuous glucose monitoring (CGM) sensor integration in the Uni
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024 results after the financial markets close on Thursday, August 1, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2024 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register.vevent.com/register/BIc1efe0f41c4149
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2024 and increased sales guidance for the year ending December 31, 2024. First Quarter 2024 Highlights Compared to First Quarter 2023: Worldwide GAAP sales increased 13 percent to $191.7 million; worldwide non-GAAP sales increased 12 percent to $192.8 million. Worldwide pump shipments increased 9 percent to approximately 25,000 pumps from 23,000 pumps. First quarter 2024 commercial launches: Launched Tandem Mobi with Dexcom G6 continuous glucose monitoring (CGM) sensor integration in the United States. Launc
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2024 results after the financial markets close on Thursday, May 2, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2024 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register.vevent.com/register/BI12c72cd6ea054b01881
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2023 and provided its financial guidance for the year ending December 31, 2024. Fourth Quarter and Recent Highlights Worldwide installed base increased 7 percent to approximately 452,000 in-warranty customers compared to the fourth quarter 2022. Launched Tandem Mobi, the world's smallest, durable Automated Insulin Delivery (AID) System in the United States. Achieved first-to-market launch with multiple, next-generation continuous glucose monitoring sensor integrations. Launched Tandem Source, a
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2023 results after the financial markets close on Wednesday, February 21, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2023 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register.veve
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2023 and updated its financial guidance for the year ending December 31, 2023. Third Quarter and Recent Highlights Worldwide installed base increased 11 percent to approximately 444,000 in-warranty customers compared to the third quarter 2022. Published prospective study data demonstrating the immediate and sustained benefit of t:slim X2 with Control-IQ technology for one year across approximately 3,000 individuals living with type 1 diabetes. Commenced initial, limited release of Tandem Mobi in the United St
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2023 results after the financial markets close on Wednesday, November 1, 2023. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2023 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register.vevent.com/register/BIef8a824a5ebe4
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2023 and updated its financial guidance for the year ending December 31, 2023. Second Quarter and Recent Highlights Worldwide installed base increased 16 percent to approximately 437,000 in-warranty customers compared to the second quarter 2022. Commenced U.S. launch of Tandem Source, a data management application designed to be a centralized digital ecosystem for customers and healthcare providers worldwide. Enrolled first participant in pivotal study for people living with type 2 diabetes using Control-IQ techno
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
3 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
U.S. stocks were higher, with the Dow Jones index surging around 200 points on Monday. Shares of Corning Incorporated (NYSE:GLW) rose sharply during Monday's session after the company increased its second-quarter core sales guidance. The company said it now projects core sales to be approximately $3.6 billion (vs. consensus of $3.41 billion), an increase from the previous guidance of $3.4 billion. Core EPS is expected to reach the high end of, or slightly exceed, the management's guided range of $0.42 to $0.46 (vs. estimate of $0.45). Corning shares jumped 9.4% to $42.05 on Monday. Here are some other big stocks recording gains in today’s session. Morphic Holding, Inc. (NASDA
In the latest quarter, 15 analysts provided ratings for Tandem Diabetes Care (NASDAQ:TNDM), showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 6 3 0 0 Last 30D 0 1 0 0 0 1M Ago 4 0 0 0 0 2M Ago 1 5 1 0 0 3M Ago 1 0 2 0 0 Analysts have recently evaluated Tandem Diabetes Care and provided 12-month price targets. The average target is $48.8, accompanied by a high estimate of $75.00 and a low estimate of $31.00. Witnessing a posit
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Susquehanna boosted the price target for Advanced Micro Devices, Inc. (NASDAQ:AMD) from $185 to $200. Susquehanna analyst Christopher Rolland maintained a Positive rating. AMD shares gained 0.7% to close at $167.87 on Friday. See how other analysts view this stock. TD Cowen cut the price target for Delek US Holdings, Inc. (NYSE:DK) from $25 to $20. TD Cowen analyst Jason Gabelman downgraded the stock from Hold to Sell. Delek US Holdings shares fell 0.6% to close at $25.28 on Friday. See how other a
Oppenheimer analyst Steven Lichtman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and raises the price target from $47 to $58.
Redburn Atlantic analyst Issie Kirby initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Buy rating and announces Price Target of $60.
Lake Street analyst Brooks O'Neil maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and raises the price target from $60 to $75.
Citigroup analyst Joanne Wuensch upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Neutral to Buy and raises the price target from $40 to $57.
11 analysts have shared their evaluations of Tandem Diabetes Care (NASDAQ:TNDM) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 5 3 0 0 Last 30D 1 0 0 0 0 1M Ago 1 5 1 0 0 2M Ago 1 0 1 0 0 3M Ago 0 0 1 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $43.82, a high estimate of $55.00, and a low estimate of $31.00. This upward trend is evident, with
Stifel analyst Mathew Blackman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and raises the price target from $45 to $55.
10-Q - TANDEM DIABETES CARE INC (0001438133) (Filer)
8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)
8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)
8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)
SD - TANDEM DIABETES CARE INC (0001438133) (Filer)
8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)
8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)
10-Q - TANDEM DIABETES CARE INC (0001438133) (Filer)
8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)
ARS - TANDEM DIABETES CARE INC (0001438133) (Filer)
SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
SC 13G - TANDEM DIABETES CARE INC (0001438133) (Subject)
SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
Goldman initiated coverage of Tandem Diabetes Care with a rating of Neutral and set a new price target of $46.00
RBC Capital Mkts initiated coverage of Tandem Diabetes Care with a rating of Outperform and set a new price target of $65.00
Morgan Stanley initiated coverage of Tandem Diabetes Care with a rating of Equal-Weight and set a new price target of $45.00
Canaccord Genuity initiated coverage of Tandem Diabetes Care with a rating of Buy and set a new price target of $57.00
Redburn Atlantic initiated coverage of Tandem Diabetes Care with a rating of Buy and set a new price target of $60.00
Citigroup upgraded Tandem Diabetes Care from Neutral to Buy and set a new price target of $57.00 from $40.00 previously
Wells Fargo upgraded Tandem Diabetes Care from Equal Weight to Overweight and set a new price target of $45.00 from $21.00 previously
Leerink Partners upgraded Tandem Diabetes Care from Market Perform to Outperform and set a new price target of $45.00 from $34.00 previously
Stifel upgraded Tandem Diabetes Care from Hold to Buy and set a new price target of $37.00 from $24.00 previously
Citigroup downgraded Tandem Diabetes Care from Buy to Neutral and set a new price target of $33.00 from $45.00 previously
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620151195/en/Jean-Claude "JC" Kyrillos (Photo: Business Wire) "JC brings deep experience in healthcare and a great balance of technical, operational, and leadership skills from multipl
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' opti
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Mark Novara as Executive Vice President and Chief Commercial Officer, effective November 13, 2023. Mr. Novara comes to Tandem with extensive global healthcare experience, having served in the diabetes, medical technology, and life sciences industries for nearly 25 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231101343981/en/Mark Novara (Photo: Business Wire) "Mark is a strategic, global leader with a successful track record of driving above market business growth, while building scalab
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Rebecca Robertson as Chair of its Board of Directors. Ms. Robertson, who joined Tandem's Board as an independent director in January 2019, succeeds Kim Blickenstaff, who will continue as a member of the Board. "We're deeply grateful to Kim for his instrumental contributions to Tandem since 2007, serving first as our CEO then as Chair for the past 4 years," said John Sheridan, President and Chief Executive Officer. "His strategic vision and mission-driven focus has helped to build and shape Tandem from a venture-backed start-up to a worldwide leader in dia
BOSTON and DURHAM, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO), today announced the promotions of Peyton Howell to the newly-created role of Chief Operating and Growth Officer and Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence. These moves are designed to strengthen the company's medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales and delivery to delight customers, build repeat business and lead the market in the next phase of drug development transformation. As Chief Operating and Growth Officer, Ms. Howell will
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Rajwant (Raj) Singh Sodhi as an independent member of its board of directors effective January 1, 2021. He will succeed Edward Cahill, who has served as a board member for the Company since May 2009. Mr. Sodhi is president of the software as a service (SaaS) business at ResMed (NYSE: RMD, ASX: RMD). He brings to the Tandem board more than 25 years of digital strategy experience, SaaS commercialization and operations across multiple industries including healthcare, financial services, and telecom. “We are pleased to w